<DOC>
	<DOCNO>NCT02144181</DOCNO>
	<brief_summary>This prospective , multi-site ( 5 site ) , single-blinded , randomized trial . Up 88 subject enrol randomized one four treatment group ( 4 Groups 22 subject ) , receive study treatment base assigned treatment group . Following study treatment , follow-up visit occur 90 , 180 365 day subject 's last study treatment .</brief_summary>
	<brief_title>Ultherapy® Treatment Erythematotelangiectatic Rosacea</brief_title>
	<detailed_description>Clinician Erythema Assessment ( CEA ) Patient Self-Assessment ( PSA ) score , assess severity erythema , obtain prior study treatment confirm subject eligibility . Enrolled subject receive three dual-depth treatment affect area midface ( cheek , chin , forehead , glabella nose ) treatment provide approximately 2 week apart . Groups A B receive low-density treatment , Groups C D receive high-density treatment . Groups A C receive 2 treatment . Groups B D receive 3 treatment . Protocol amend Sept 2014 : Groups A C receive 1 treatment ; Groups B D receive 2 treatment .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>1 . Male female , age 18 65 year . 2 . Subject good health . 3 . Clinical diagnosis Erythematotelangiectatic Rosacea . 4 . Understands accepts obligation undergo elective procedure , i.e. , laser IPL , area treat followup period . 5 . A Clinician Erythema Assessment ( CEA ) score great equal 3 Screening Baseline/Day 0 ( prior study treatment commencement ) . 6 . A Patient SelfAssessment ( PSA ) erythema score great equal 2 Screening Baseline/Day 0 ( prior study treatment commencement ) . 7 . Willingness refrain use aspirin , Ibuprofen , Naproxen NSAID prior study treatment chronic use entire posttreatment study period . Washout period , chronic user , 4 week prior first treatment . After study treatment complete , limited acute NSAID use allow . A maximum 23 dos , 2 week prior study followup visit allow , need . 8 . Willingness continue use current skin care topical treatment regimen entire study period ( 1 year ) . 9 . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study , unless deem medically necessary . 10 . Subjects childbearing potential must negative urine pregnancy test result must lactate Visit 1 willing able use acceptable method birth control . 11 . Absence physical psychological condition unacceptable investigator . 12 . Willingness ability provide write consent studyrequired photography adherence photography procedure ( i.e. , removal jewelry makeup ) . 13 . Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure . 1 . Presence active systemic disease may affect wound healing . 2 . More 5 prominent telangiectases ( &gt; 0.2mm width , width thick human hair , image provide ) area ( ) treat , exception lateral side nose . 3 . Particular form rosacea ( papulopustular , phymatous , ocular Rosacea , rosacea conglobata , rosacea fulminans , isolated rhinophyma , isolated pustulosis chin ) concomitant facial dermatosis similar rosacea perioral dermatitis , demodicidosis , facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus . 4 . Presence three ( 3 ) facial inflammatory lesion ( papule pustule ) rosacea . 5 . Current treatment monoamine oxidase ( MAO ) inhibitor , barbiturate , opiate , sedative , systemic anesthetic , alpha agonist . 6 . Intense flush trigger , postmenopausal hot flash particular food , versus intense less intense flushing several common trigger . 7 . Less 3 month stable dose treatment tricyclic antidepressant , cardiac glycoside , beta blocker antihypertensive agent vasodilation MOA ( e.g. , calcium channel blocker , nifedipine ) . 8 . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sjögren 's syndrome , clinically diagnose depression ( unless stable treatment regimen . ) 9 . History postinflammatory hyperpigmentation . 10 . Severe solar elastosis . 11 . Significant scar would interfere assess result area treat . 12 . Open wound lesion area ( ) treat . 13 . Acne . 14 . Active implant ( e.g. , pacemaker defibrillator ) , metallic implant treatment area ( dental implant include . ) 15 . Inability understand protocol give inform consent . 16 . Microdermabrasion glycolic acid peel treatment area within four week prior study participation study . 17 . Marked asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin area ( ) treat . 18 . History chronic drug alcohol abuse . 19 . History autoimmune disease . 20 . History Bell 's Palsy epilepsy 21 . History diabetes . 22 . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . 23 . Subjects anticipate need inpatient surgery overnight hospitalization study . 24 . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . 25 . Concurrent enrollment , participate within past 30 day , study involve use investigational device drug . 26 . Current smoker history smoking last five year . 27 . Current user nicotinecontaining product , e.g. , ecigarettes , Nicorette gum , nicotine patch , etc . 28 . History follow cosmetic treatment area treat : 1 . Skin tighten procedure within past year ; 2 . Injectable filler type within past : . 12 month Hyaluronic acid filler ( e.g. , Restylane ) ii . 12 month Ca Hydroxyapatite filler ( e.g. , Radiesse ) iii . 24 month Longlasting Hyaluronic acid ( Juvéderm Voluma ) PolyLLactic acid filler ( e.g. , Sculptra ) iv . Ever permanent filler ( e.g. , Silicone , ArteFill ) c. Neurotoxins within past three month ; d. Ablative resurface laser treatment ; e. Nonablative , rejuvenative laser light treatment within past six month ; f. Surgical dermabrasion deep facial peel ; 29 . History use Accutane systemic retinoids within past six month ; 30 . Topical retinoids within past two week ; 31 . Antiplatelet agent / Anticoagulants ( Coumadin , Heparin , Plavix ) ; 32 . Chronic use nonsteroidal antiinflammatories ( naproxen , ibuprofen , etc . ) within past 4 week . 33 . Psychiatric drug investigator opinion would impair subject understand protocol requirement , understand signing informed consent , affect ability accurately complete QOL subjective improvement assessment . 34 . Use Mirvaso ( topical brimonidine tartrate ) within previous two week . 35 . Use systemic corticosteroid immunosuppressive drug . 36 . Use antipruritic , include antihistamine , within 24 hour study visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ulthera® System</keyword>
	<keyword>Ultherapy® Treatment</keyword>
	<keyword>Ulthera , Inc .</keyword>
</DOC>